Latest News

Thursday, April 28, 2016 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension

Ocular Therapeutix announced that it has completed its end-of-phase 2 review with the FDA for its OTX-TP (sustained-release travoprost) product candidate for the treatment of glaucoma and ocular hyper…

Read the full story

Thursday, April 28, 2016 | Clinical Trials, NightstaRx

NightstaRx Reports Long-Term Benefits of Gene Therapy for Inherited Form of Progressive Blindness

NightstaRx announced the publication from the University of Oxford of promising clinical results and long-term benefits of choroideremia gene therapy in this week’s issue of the New England Jour…

Read the full story

Thursday, April 28, 2016 | Health Care, Valeant

Senate Committee Condemns Valeant's Business Model

The Senate Committee on Aging criticized Valeant's business model, with committee members saying that investors played an “outsized role” in the company's decision-making and that …

Read the full story

Thursday, April 28, 2016 | Product Releases

Icare Unveils the ic100 Handheld Tonometer Featuring Several Design Upgrades

Icare USA, a subsidiary of Icare Finland, announced the release of the Icare ic100 tonometer, according to a company news release. The Icare ic100 uses the same rebound technology as its success…

Read the full story

Thursday, April 28, 2016 | Conferences, Clearside Biomedical

Clearside Biomedical to Present Data on Suprachoroidal Drug Administration at 2016 ARVO Meeting

Clearside Biomedical announced four poster presentations associated with suprachoroidal drug administration will be presented at the 2016 Annual Meeting of the Association for Research in Vision and O…

Read the full story

Thursday, April 28, 2016 | Conferences, Glaucoma, Glaukos Corporation

Glaukos Featured in Numerous Presentations at 2016 American Society of Cataract and Refractive Surgery

Glaukos announced that its products will be featured in numerous presentations at the annual American Society of Cataract and Refractive Surgery (ASCRS) meeting being held at the Ernest N. Morial Conv…

Read the full story

Thursday, April 28, 2016 | Management/Leadership, Ophthotech

Carmen A. Puliafito, MD, MBA, Former Dean of Keck School of Medicine of the University of Southern California, Joins Ophthotech as Chief of Strategic Development

Ophthotech announced the appointment of Carmen A. Puliafito, MD, MBA, as Chief of Strategic Development, according to a company news release. As one of the world's leading experts in ophthalmol…

Read the full story

Thursday, April 28, 2016 | Medical Studies

Gene Therapy for Choroideremia Improves Vision After 3.5 Years

An experimental gene therapy continued to improve the vision of some patients with choroideremia at 3.5 years of follow-up in a phase 1/2 clinical trial. In showing efficacy for this length of time, t…

Read the full story

Wednesday, April 27, 2016 | Conferences, Envision

Envision Names Joshua A. Miele, PhD, Keynote Speaker at Annual Envision Conference

Envision announced that Joshua A. Miele, PhD, founder and director of the Video Description Research and Development Center and associate director of the Smith-Kettlewell Eye Research Institute in San…

Read the full story

Wednesday, April 27, 2016 | Miscellaneous

Deaf Toddler With Pediatric Glaucoma Travels To US To Undergo Surgery, Sees And Hears Mom For First Time

Nicolly Pereira went through seven failed surgeries in Brazil before coming to America to heal her pediatric glaucoma and blindness. The 2-year-old girl had been unable to see or hear since birth, but…

Read the full story

Wednesday, April 27, 2016 | Earnings & Financials, Valeant

Valeant Was Too Aggressive in Raising Drug Prices, CEO Says

Valeant Pharmaceuticals International Inc. has made mistakes and been too aggressive in the past in dramatically boosting ​the ​price​ of some of its drugs, the company's outgoing chief ex…

Read the full story

Wednesday, April 27, 2016 | Conferences, Omeros

Omeros Announces Independent Studies with Omidria to Be Presented at Upcoming Ophthalmology Congresses

Omeros announced that new research related to the clinical utility of Omidria (phenylephrine and ketorolac injection) 1% / 0.3% and the importance of preempting intraoperative miosis and inflammation …

Read the full story

Wednesday, April 27, 2016 | Medical Studies

Gene Therapy Promising for Rare Eye Disease

Nine of 12 patients with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD) had improved visual function after gene therapy in a phase 1 trial led by resear…

Read the full story

Tuesday, April 26, 2016 | Conferences, Bausch+Lomb

Bausch + Lomb Announces Portfolio Enhancements, Expansion, and ASCRS Activity

Bausch + Lomb distributed a letter to US eye care professionals today highlighting the recent FDA approval of several enhancements to B+L’s Trulign Toric IOL calculator and the company's pla…

Read the full story

Tuesday, April 26, 2016 | Conferences, Allergan

Allergan Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle

Allergan announced that its data will be presented during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington, May 1-5, 2016. This data span…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $16.02  0.31% 
 Akorn, Inc. $25.43  -2.60% 
 Alimera Sciences, Inc. $2.36  0.00% 
 Allergan $218.85  -0.55% 
 Avalanche Biotechnologies $5.68  -1.22% 
 Bayer $114.63  -3.12% 
 Can-Fite Biopharma $2.89  -0.69% 
 Carl Zeiss Meditec $28.78  0.47% 
 Cooper Companies, Inc. $155.80  -1.42% 
 Eleven Biotherapeutics $0.89  -7.29% 
 Escalon Medical Corp. $0.80  0.00% 
 Essilor International $125.75  0.00% 
 Glaukos $18.75  -0.37% 
 Imprimis Pharmaceuticals, Inc. $3.93  0.77% 
 Inotek Pharmaceuticals $9.40  0.11% 
 InSite Vision, Inc. $0.35  0.00% 
 IRIDEX Corporation $11.41  3.35% 
 Johnson & Johnson $112.48  -0.26% 
 Luxottica Group, S.p.A. $52.73  -1.70% 
 Merck & Company, Inc. $55.74  -1.01% 
 NicOx $8.73  1.19% 
 NovaBay Pharmaceuticals, Inc. $2.75  13.17% 
 Novartis AG Common Stock $76.81  -0.22% 
 Ocular Therapeutix $12.67  1.36% 
 Ophthotech Corporation $47.88  -0.91% 
 QLT $1.49  0.00% 
 Quantel $3.55  0.57% 
 Regeneron $391.30  0.26% 
 Roche $31.72  -1.03% 
 Second Sight Medical Products $5.06  -5.24% 
 Shire $180.96  -0.30% 
 STAAR Surgical Company $7.68  -1.79% 
 TearLab Corporation $0.79  5.32% 
 Thrombogenics $3.70  0.00% 
 Topcon Corporation $12.53  -1.73% 
 TriVascular Technologies, Inc. $5.87  0.00% 
 Valeant Pharmaceuticals $35.25  0.95% 
 Xoma $0.88  -2.96%